Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -2.94%34.87B | 3.98%148.48B | 9.44%35.93B | 3.42%142.79B | 1.74%34.97B | 8.03%39.42B | 1.34%35.58B | 2.26%32.83B | 7.36%138.06B | 9.45%34.37B |
| Cost of revenue | -3.46%22.83B | 6.06%97.63B | 10.65%23.64B | 7.34%92.05B | 6.39%22.44B | 7.25%25.06B | 6.73%23.18B | 9.17%21.37B | 11.21%85.75B | 7.05%21.09B |
| Gross profit | -1.94%12.04B | 0.22%50.85B | 7.17%12.28B | -3.00%50.74B | -5.64%12.53B | 9.43%14.36B | -7.39%12.4B | -8.53%11.46B | 1.60%52.31B | 13.49%13.28B |
| Operating expense | 2.86%10.88B | 8.30%43.9B | 7.56%10.58B | -0.17%40.53B | 0.14%9.99B | 3.08%10.49B | -3.30%10.22B | -0.48%9.83B | 4.35%40.6B | 4.07%9.98B |
| Staff costs | ---- | 8.45%10.79B | ---- | 4.20%9.95B | ---- | ---- | ---- | ---- | 3.41%9.55B | ---- |
| Selling and administrative expenses | ---- | 10.07%23.98B | ---- | -4.17%21.79B | ---- | ---- | ---- | ---- | 6.20%22.73B | ---- |
| -Selling and marketing expense | ---- | -0.80%3.46B | ---- | 7.52%3.49B | ---- | ---- | ---- | ---- | 4.51%3.24B | ---- |
| -General and administrative expense | ---- | 12.14%20.52B | ---- | -6.11%18.3B | ---- | ---- | ---- | ---- | 6.49%19.49B | ---- |
| Research and development costs | ---- | -6.76%1.08B | ---- | -6.56%1.15B | ---- | ---- | ---- | ---- | -6.52%1.23B | ---- |
| Depreciation and amortization | ---- | 1.09%465M | ---- | -13.21%460M | ---- | ---- | ---- | ---- | -38.66%530M | ---- |
| -Depreciation | ---- | 1.09%465M | ---- | -13.21%460M | ---- | ---- | ---- | ---- | -38.66%530M | ---- |
| Other operating expenses | ---- | 5.61%7.59B | ---- | 9.58%7.18B | ---- | ---- | ---- | ---- | 7.76%6.56B | ---- |
| Operating profit | -31.67%1.17B | -31.86%6.96B | 4.86%1.71B | -12.82%10.21B | -23.11%2.54B | 31.40%3.87B | -22.71%2.18B | -38.60%1.63B | -6.93%11.71B | 56.22%3.3B |
| Net non-operating interest income (expenses) | -800.00%-77M | -654.84%-172M | 161.11%11M | 186.11%31M | 235.71%19M | -266.67%-11M | 4,200.00%41M | 0.00%-18M | 57.14%-36M | 33.33%-14M |
| Non-operating interest income | -30.95%29M | 1.32%154M | 75.00%42M | 90.00%152M | 233.33%50M | 73.08%45M | 17.86%33M | 118.18%24M | 158.06%80M | 87.50%15M |
| Non-operating interest expense | 241.94%106M | 169.42%326M | -26.19%31M | 4.31%121M | 6.90%31M | 93.10%56M | -127.59%-8M | 44.83%42M | 0.87%116M | 0.00%29M |
| Net investment income | -132.15%-181M | -60.71%556M | -38.20%563M | 75.34%1.42B | 341.95%769M | -24.29%-696M | 31.00%431M | 5.44%911M | -5.06%807M | -68.19%174M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 839.13%432M | 4,700.00%46M | 0 | 46M | -1M | -110.00%-1M | ||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | -47.62%-31M | -180.39%-1.16B | -250.00%-21M | -227.78%-413M | -6.67%-112M | 44.44%-5M | -5,700.00%-290M | 14.29%-6M | -129.51%-126M | -377.27%-105M |
| Less:Other special charges | 47.62%31M | 3,305.88%1.16B | 250.00%21M | -70.43%34M | -87.23%12M | -44.44%5M | 120.00%11M | -14.29%6M | 126.93%115M | 327.27%94M |
| Less:Write off | ---- | --0 | ---- | 3,345.45%379M | 809.09%100M | --0 | ---- | ---- | --11M | --11M |
| Other non-operating income (expenses) | -19.64%45M | 8.29%222M | 40.00%56M | -37.69%205M | -44.74%63M | -38.20%55M | -32.86%47M | -28.57%40M | 28.02%329M | 159.09%114M |
| Income before tax | -60.29%919M | -40.53%6.83B | -9.36%2.31B | -9.39%11.49B | -5.46%3.27B | 32.21%3.26B | -24.98%2.41B | -27.98%2.55B | -9.62%12.68B | 29.82%3.46B |
| Income tax | -63.48%237M | 26.47%4.27B | -17.43%649M | -6.87%3.38B | -13.42%826M | 31.54%951M | -13.21%815M | -22.26%786M | -5.23%3.63B | 50.00%954M |
| Net income | -59.04%682M | -68.43%2.56B | -5.77%1.67B | -10.40%8.11B | -2.43%2.45B | 32.49%2.3B | -29.90%1.59B | -30.24%1.77B | -11.27%9.05B | 23.50%2.51B |
| Net income continuous operations | -59.04%682M | -68.43%2.56B | -5.77%1.67B | -10.40%8.11B | -2.43%2.45B | 32.49%2.3B | -29.85%1.59B | -30.27%1.77B | -11.26%9.05B | 23.50%2.51B |
| Noncontrolling interests | -262.50%-13M | -445.24%-145M | -20.00%8M | 223.08%42M | 4M | 15M | 116.67%13M | 42.86%10M | -75.47%13M | 0 |
| Net income attributable to the company | -58.03%695M | -66.45%2.71B | -5.69%1.66B | -10.74%8.07B | -2.59%2.44B | 31.63%2.29B | -30.32%1.58B | -30.46%1.76B | -10.93%9.04B | 24.23%2.51B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -58.03%695M | -66.45%2.71B | -5.69%1.66B | -10.74%8.07B | -2.59%2.44B | 31.63%2.29B | -30.32%1.58B | -30.46%1.76B | -10.93%9.04B | 24.23%2.51B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -56.36%20.52 | -64.89%78.49 | -2.75%47.02 | -9.56%223.57 | -0.91%68.26 | 33.27%63.41 | -29.52%43.55 | -29.88%48.35 | -10.80%247.21 | 25.00%68.89 |
| Diluted earnings per share | -56.35%20.48 | -64.90%78.32 | -2.76%46.92 | -9.54%223.13 | -0.90%68.12 | 33.22%63.28 | -29.52%43.48 | -29.81%48.25 | -10.72%246.67 | 25.16%68.74 |
| Dividend per share | 0 | 0.00%114 | 0 | 17.53%114 | 17.53%57 | 0 | 17.53%57 | 0 | 0.00%97 | -11.82%48.5 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |